Archive


Category: Disarm Therapeutics

  • Top 20 Biopharma M&A of 2020 by Total Deal Value

    Biopharma merger and acquisition activity in 2020 was mainly filled with late-stage, bolt-on acquisitions, which were orders of magnitude smaller than the mega M&A deals of prior years. AstraZeneca holds the top rank by acquiring Alexion Pharmaceuticals among the top 20 acquisitions with a total deal value of $39B at a 1-day premium of 45% […]

  • Eli Lily to Acquire Disarm Therapeutics for ~$1.36B

    Shots: Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B The acquisition will expand Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s preclinical SARM1 programs for axonal degeneration Disarm is advancing its potent SARM1 inhibitors in preclinical […]

  • Lilly to buy private biotech Disarm Therapeutics for up to $1.36bn

    Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion. Massachusetts-based Disarm is focused on treatments for diseases caused by axonal degeneration, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis. Disarm has discovered […]